Logo image of HLTH

CUE HEALTH INC (HLTH) Stock Fundamental Analysis

NASDAQ:HLTH - Nasdaq - US2297901009 - Common Stock - Currency: USD

0.0434  -0.02 (-29.77%)

After market: 0.0489 +0.01 (+12.67%)

Fundamental Rating

3

Taking everything into account, HLTH scores 3 out of 10 in our fundamental rating. HLTH was compared to 188 industry peers in the Health Care Equipment & Supplies industry. While HLTH seems to be doing ok healthwise, there are quite some concerns on its profitability. HLTH is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

HLTH had negative earnings in the past year.
HLTH had a negative operating cash flow in the past year.
HLTH had negative earnings in 4 of the past 5 years.
HLTH had negative operating cash flow in 4 of the past 5 years.
HLTH Yearly Net Income VS EBIT VS OCF VS FCFHLTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 0 100M -100M -200M -300M

1.2 Ratios

HLTH has a Return On Assets of -109.92%. This is amonst the worse of the industry: HLTH underperforms 81.68% of its industry peers.
Looking at the Return On Equity, with a value of -149.25%, HLTH is doing worse than 76.44% of the companies in the same industry.
Industry RankSector Rank
ROA -109.92%
ROE -149.25%
ROIC N/A
ROA(3y)-42.89%
ROA(5y)-43.77%
ROE(3y)-56.89%
ROE(5y)-73.2%
ROIC(3y)N/A
ROIC(5y)N/A
HLTH Yearly ROA, ROE, ROICHLTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -50 -100

1.3 Margins

HLTH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HLTH Yearly Profit, Operating, Gross MarginsHLTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -200 -400

More info and screens

6

2. Health

2.1 Basic Checks

HLTH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HLTH has been increased compared to 1 year ago.
Compared to 1 year ago, HLTH has an improved debt to assets ratio.
HLTH Yearly Shares OutstandingHLTH Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 50M 100M 150M
HLTH Yearly Total Debt VS Total AssetsHLTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -4.83, we must say that HLTH is in the distress zone and has some risk of bankruptcy.
HLTH's Altman-Z score of -4.83 is on the low side compared to the rest of the industry. HLTH is outperformed by 68.59% of its industry peers.
There is no outstanding debt for HLTH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.83
ROIC/WACCN/A
WACC9.06%
HLTH Yearly LT Debt VS Equity VS FCFHLTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

HLTH has a Current Ratio of 2.54. This indicates that HLTH is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of HLTH (2.54) is comparable to the rest of the industry.
A Quick Ratio of 2.22 indicates that HLTH has no problem at all paying its short term obligations.
HLTH's Quick ratio of 2.22 is in line compared to the rest of the industry. HLTH outperforms 47.12% of its industry peers.
Industry RankSector Rank
Current Ratio 2.54
Quick Ratio 2.22
HLTH Yearly Current Assets VS Current LiabilitesHLTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for HLTH have decreased strongly by -153.47% in the last year.
The Revenue for HLTH has decreased by -85.32% in the past year. This is quite bad
Measured over the past years, HLTH shows a very strong growth in Revenue. The Revenue has been growing by 45.56% on average per year.
EPS 1Y (TTM)-153.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-357.14%
Revenue 1Y (TTM)-85.32%
Revenue growth 3Y45.56%
Revenue growth 5YN/A
Sales Q2Q%-87.19%

3.2 Future

HLTH is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.29% yearly.
HLTH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 52.69% yearly.
EPS Next Y56.3%
EPS Next 2Y31.95%
EPS Next 3Y24.25%
EPS Next 5Y17.29%
Revenue Next Year-18.38%
Revenue Next 2Y25.41%
Revenue Next 3Y43.74%
Revenue Next 5Y52.69%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
HLTH Yearly Revenue VS EstimatesHLTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
HLTH Yearly EPS VS EstimatesHLTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 -1 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

HLTH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year HLTH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HLTH Price Earnings VS Forward Price EarningsHLTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HLTH Per share dataHLTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as HLTH's earnings are expected to grow with 24.25% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.95%
EPS Next 3Y24.25%

More info and screens

0

5. Dividend

5.1 Amount

HLTH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CUE HEALTH INC

NASDAQ:HLTH (6/5/2024, 8:00:01 PM)

After market: 0.0489 +0.01 (+12.67%)

0.0434

-0.02 (-29.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-13 2024-05-13/amc
Earnings (Next)08-07 2024-08-07/amc
Inst Owners1.03%
Inst Owner Change0%
Ins Owners29.79%
Ins Owner Change0%
Market Cap6.90M
Analysts43.33
Price Target0.51 (1075.12%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-56.92%
Min EPS beat(2)-120.16%
Max EPS beat(2)6.32%
EPS beat(4)1
Avg EPS beat(4)-29.65%
Min EPS beat(4)-120.16%
Max EPS beat(4)6.32%
EPS beat(8)5
Avg EPS beat(8)14.83%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)3.53%
Min Revenue beat(2)2.82%
Max Revenue beat(2)4.24%
Revenue beat(4)3
Avg Revenue beat(4)-3.72%
Min Revenue beat(4)-27.41%
Max Revenue beat(4)5.48%
Revenue beat(8)7
Avg Revenue beat(8)33.33%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-33.33%
PT rev (3m)-52.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-46.75%
EPS NY rev (1m)0%
EPS NY rev (3m)-26.54%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-65.07%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-38.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.1
P/FCF N/A
P/OCF N/A
P/B 0.03
P/tB 0.03
EV/EBITDA N/A
EPS(TTM)-2.56
EYN/A
EPS(NY)-1.12
Fwd EYN/A
FCF(TTM)-0.99
FCFYN/A
OCF(TTM)-0.87
OCFYN/A
SpS0.45
BVpS1.57
TBVpS1.45
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -109.92%
ROE -149.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.89%
ROA(5y)-43.77%
ROE(3y)-56.89%
ROE(5y)-73.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.18%
Cap/Sales 27.9%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.54
Quick Ratio 2.22
Altman-Z -4.83
F-Score3
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)177.13%
Cap/Depr(5y)371.33%
Cap/Sales(3y)19.89%
Cap/Sales(5y)88.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-153.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-357.14%
EPS Next Y56.3%
EPS Next 2Y31.95%
EPS Next 3Y24.25%
EPS Next 5Y17.29%
Revenue 1Y (TTM)-85.32%
Revenue growth 3Y45.56%
Revenue growth 5YN/A
Sales Q2Q%-87.19%
Revenue Next Year-18.38%
Revenue Next 2Y25.41%
Revenue Next 3Y43.74%
Revenue Next 5Y52.69%
EBIT growth 1Y-45.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.74%
EBIT Next 3Y13.08%
EBIT Next 5Y20.63%
FCF growth 1Y9.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.13%
OCF growth 3YN/A
OCF growth 5YN/A